title: Pretreatment 14-3-3 epsilon level is predictive for advanced extranodal NK/T cell lymphoma therapeutic response to asparaginase-based chemotherapy.
abstract: The aim of the present study was to identify the potential relevant biomarkers to predict the therapeutic response of advanced extranodal natural killer/T cell lymphoma(ENKTL) treated with asparaginase-based treatment.
  
  
  
  Proteomic technology is used to identify differentially expressed proteins between chemotherapy-resistant and chemotherapy-sensitive patients. Then enzyme-linked immunosorbent assay is used to validate the predictive value of selective biomarkers.
  
  
  
  A total of 61 upregulated and 22 downregulated proteins are identified in chemotherapy-resistant patients compared with chemotherapy-sensitive patients. Furthermore, they validated that pretreatment high level 14-3-3 epsilon(ε)(≥61.95 ng/mL, 84.0 and 95.2% for sensitivity and specificity, respectively) is associated with poor 2-year overall survival (OS) (5.3 vs 68.8%, p<0.0001) and PFS (4.5 vs 76.9%, p<0.0001). In multivariate survival analysis, pretreatment high level 14-3-3 epsilon significantly is correlated with both inferior OS (p = 0.033) and PFS (p = 0.005).
  
  
  
  These findings indicate that pretreatment high level 14-3-3 epsilon is an independent predictor of chemotherapy-resistance and poor prognosis for patients with advanced ENKTL in the era of asparaginase.
authors: Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
authors: Yajuan
authors: Y
authors: Qiu
authors: Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
authors: Zhiyuan
authors: Z
authors: Zhou
authors: Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
authors: Zhaoming
authors: Z
authors: Li
authors: Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
authors: Lisha
authors: L
authors: Lu
authors: Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
authors: Ling
authors: L
authors: Li
authors: Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
authors: Xin
authors: X
authors: Li
authors: Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
authors: Xinhua
authors: X
authors: Wang
authors: Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
authors: Mingzhi
authors: M
authors: Zhang
mesh_terms: D048948:14-3-3 Proteins / Q000378:metabolism*; D000293:Adolescent; D000328:Adult; D000368:Aged; D001215:Asparaginase / Q000494:pharmacology* / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood; D018572:Disease-Free Survival; D015536:Down-Regulation / Q000187:drug effects; D005260:Female; D006801:Humans; D054391:Lymphoma, Extranodal NK-T-Cell / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D040901:Proteomics; D016896:Treatment Outcome; D015854:Up-Regulation / Q000187:drug effects; D055815:Young Adult
chemical_list: D048948:14-3-3 Proteins; D014408:Biomarkers, Tumor; D001215:Asparaginase
keywords: 14-3-3 epsilon; Asparaginase; Extranodal NK/T cell lymphoma; Prognosis